Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?

  • Published:  09 October 2020
  • Likes: 

    Heart Icon

    1

Up Next

Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?

  • Published:  09 October 2020
  • Likes: 

    Heart Icon

    1

Average (ratings)
No ratings
Your rating
Overview

This educational symposium was originally broadcast as part of the ESC 2020 Digital Congress.

 

The programme focuses on summarising recent data on SGLT2 inhibitors showing reductions in CV risk, HF hospitalisations  and mortality, as well as improved quality-of-life. The expert panel also discuss how these agents should be introduced into clinical practice and contemporary heart failure guidelines for both diabetics and non-diabetics.

This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

Learning Objectives

  • Discuss Current SGLT2 Data and Guideline Recommendations for Utilization in Heart Failure
  • Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors
  • Understand the Implications of Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors

More from this programme

Part 1

SGLT2s as a Heart Failure Drug – How Did We Get Here?

Part 2

Emerging Data SGLT2 Inhibitors in Heart Failure

Part 3

Guidelines and Practice Implications

Part 4

Q&A Discussion

Part 5

Follow-up Peer-to Peer Discussion

Faculty Biographies

Andrew JS Coats

Andrew JS Coats

Professor of Cardiology and Scientific Director

Professor Andrew Coats was born in Melbourne, Australia. He studied at St Catherine’s College, Oxford, where he earned a B.A. in Physiological Sciences with First-Class Honours, and then completed his medical degree (M.B. B.Chir.) at Clare College, Cambridge. He later obtained higher doctorates (D.M. and D.Sc.) in recognition of his substantial contributions to cardiovascular medicine, and he also completed an MBA at the London Business School. Professor Coats serves as Editor-in-Chief of the Cardiac Failure Review journal.

 

Career Overview

Andrew Coats is an internationally renowned academic cardiologist, inventor, and university leader with a career spanning more than three decades. He is currently the Scientific Director and CEO of the Heart Research Institute in Sydney, Australia. He also serves as Dean of the Royal Australasian College of Physicians, Affiliate Professor at Deakin University, and Emeritus Professor of Medicine at Monash University.

View full profile
Faiez Zannad

Faiez Zannad

Professor Emeritus; Founder and Chairman of CVCT Société Civile

Prof Faiez Zannad was born in Monastir, Tunisia in 1951 and later moved to pursue his medical education and research in Europe. He trained in cardiology and pharmacology across institutions in France and the United Kingdom, including Nancy, Lyon, and Oxford. Over the course of his career, he has lived and worked primarily in Nancy, France, where he has held clinical, academic, and research leadership roles in cardiovascular medicine and therapeutics.

 

Academic History

Prof Zannad earned his MD in cardiology from the Faculté de Médecine de Nancy and further trained as a research fellow in clinical pharmacology at the Medical Research Council in Oxford. He later received a PhD in cardiovascular clinical pharmacology from the University of Lyon. During his academic training, he focused on cardiovascular pharmacology, physiology, and therapeutic innovation, laying the foundation for his lifelong work in heart failure and hypertension research.

Following…

View full profile